Tag:

coronary artery disease

Latest Headlines

Latest Headlines

GlaxoSmithKline tees up another huge cardio PhIII after darapladib flop

After a costly string of defeats with the heart drug darapladib, GlaxoSmithKline's cardio unit is rolling into Phase III with another cardiac hopeful, launching an expansive late-stage effort for losmapimod, designed to prevent repeat heart attacks.

Boston Scientific buyout threatens Cardiovascular Systems

Following news of Boston Scientific's purchase of Bayer's device unit, investors punished fellow peripheral device maker Cardiovascular Systems because it is now less likely to be bought over by the device giant.

CardioDx revives IPO plans with infusion of fresh leadership

CardioDx, the heart disease test developer that delayed plans to go public in November due to poor market conditions, has decided to test the IPO waters again. This time it will be doing it with some new leadership.

Danish trial results show stem cells improve failing hearts

Results from a clinical trial of 59 patients with chronic ischemic heart disease and severe heart failure found that a new stem cell treatment improved heart pump function compared to the placebo group.

OrbusNeich starts up a U.S.-Japan trial of its dual-therapy stent

OrbusNeich has enrolled its first patient in a two-country proof-of-concept study for its innovative dual-therapy stent.

Biotronik kicks off absorbable stent trial as market crowds

Germany's Biotronik has treated its first patient in a multi-center trial of its bioabsorbable vascular scaffold, a study aimed at winning a CE mark for the coronary artery disease-treating device.

Abbott rides next-gen Xience stent into Japan

Abbott Laboratories won Japanese approval for its Xience Xpedition drug-eluting stent, plotting to launch the device in one of the world's largest markets and pad sales in its flagging vascular business.

Abbott CE mark covers extra-long stent size

In the fiercely competitive global stent market, Abbott seems to view size as mattering most.

Elixir snags CE mark for dissolvable stent

While Abbott Laboratories leads the way in the dissolvable stent market, California's Elixir Medical is right on its heels, winning CE mark approval for the DESolve device.

Cardiovascular Systems completes PMA submission

Cardiovascular Systems can now add a PMA submission to its aggressively confident 2013. The Minnesota company said it completed a premarket approval application with the FDA for a new device designed to treat calcified coronary arteries.